Information Provided By: 
Fly News Breaks for August 22, 2017
RVNC
Aug 22, 2017 | 08:32 EDT
JMP Securities analyst Donald Ellis started coverage of Revance with a $34 price target and an Outperform rating. He says that the efficacy of the company's RT002 injectable botulinum toxin appears to last six months, versus three months for competing treatments. The analyst thinks that Revance's treatment "will have cost and quality-of-life benefits for patients," and he expects the stock to rise going forward.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
